The below average efficacy of last year’s influenza vaccine (which was only 20 to 30 percent effective) can be attributed to a mutation in the H3N2 strain, a new study reports. With the mutation, most people receiving the egg-grown vaccine did not have immunity against H3N2 viruses that circulated last year.
People with RA who stop taking methotrexate treatment for just two weeks after they have a seasonal flu shot can improve the vaccine’s efficacy without increasing RA disease activity, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.
A new study explores how herpes simplex virus might change when passed from one individual to another, information that may prove useful in future development of therapeutics and vaccines.
Researchers have developed a vaccine candidate that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons following testing in mouse and ferret models.
Egg-based production causes virus to target bird cells, making vaccine less effective.
Australia has seen its worst flu season on record and could indicate a rough season for the United States.
Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.
The Association of American Cancer Institutes, the American Cancer Society, Inc., and the Centers for Disease Control and Prevention’s National Center For Immunization and Respiratory Diseases announced 10 award winners as part of its HPV Vaccine Is Cancer Prevention campaign.
Male collegiate athletes have high rates of risk factors for infection with the cancer-causing human papillomavirus (HPV), but have low HPV vaccination rates and low awareness of their personal health risks, according to a study in the November issue of The Nurse Practitioner, published by Wolters Kluwer.
It’s human nature to be afraid of pain. UCLA Health offers advice on how to get through the flu shot.
Researchers combined the immune response created by injection of potato virus nanoparticles with doxorubicin to halt melanoma progression in a mouse model. It is the first demonstration of an anti-tumor response using potato virus nanoparticle vaccination—a novel treatment further enhanced with doxorubicin chemotherapy.
Researchers have discovered that a virus-like particle vaccine can prime the body’s immune response and prevent the severe respiratory disease that results when patients given an early form of a vaccine for respiratory syncytial virus (RSV) are exposed to RSV, according to a study led by Georgia State University.
A new vaccine under development provoked an immune response to 72 forms of the bacteria that’s responsible for pneumonia, sepsis and meningitis. That’s up from the 23 forms of bacteria covered by current immunizations. The new vaccine, which represents the “most comprehensive” coverage of pneumococcal disease to date, could greatly reduce the number of deaths from the disease.
In 2013, an influenza virus began circulating among poultry in China. It caused several waves of human infection and as of late July 2017, nearly 1,600 people had tested positive for avian H7N9. Nearly 40 percent of those infected had died. In 2017, Yoshihiro Kawaoka of the University of Wisconsin-Madison received a sample of H7N9 virus isolated from a patient in China who had died of the flu. He and his research team subsequently began work to characterize and understand it.
St. Jude Children’s Research Hospital investigators said the results reinforce the importance of hand washing and other measures to help protect vulnerable patients from influenza infections.
Certain proteins in the influenza virus remain constant year after year. Researchers at Cornell University are taking one of those conserved proteins, Matrix-2 (M2), and packaging it in a nanoscale, controlled-release “capsule” in an attempt to create a quick-acting, long-lasting, multi-strain vaccine against pandemic influenza A.
A new generation DNA-based Zika vaccine is the first to demonstrate both safety and the ability to elicit an immune response against Zika in humans, according to new research from the Perelman School of Medicine at the University of Pennsylvania, conducted in partnership with The Wistar Institute, Inovio Pharmaceuticals, and GeneOne Life Science, Inc. In results published today in the New England Journal of Medicine, the phase 1 clinical trial showed for the first time that humans who received up to three doses of the vaccine candidate produced an immune response against Zika with minimal adverse effects, opening the door to further clinical trials for this important vaccine candidate.
If you diabetes and haven’t been vaccinated, it’s time to reconsider. Flu can be more serious than you realize, and health officials say there are early signs that this flu season will be a bad one.
There are several types of gynecologic cancers that affect the female reproductive system, including endometrial, ovarian, cervical, vaginal and vulvar cancer.
Each year, the flu season is a bit of a guessing game. While much is left to chance, some things can be done to plan for and prevent influenza, which is responsible for thousands of deaths each year nationwide.
A collaboration among research institutions, private industry, and the US Government will develop a tetravalent vaccine to protect against four viruses that can be fatal
For years, medical investigators have tried and failed to develop vaccines for a type of staph bacteria associated with the deadly superbug MRSA. But a new study by Cedars-Sinai investigators shows how staph cells evade the body’s immune system, offering a clearer picture of how a successful vaccine would work.
Expanding the high-dose influenza vaccine recommendation to include middle-aged adults with chronic health conditions may make economic sense and save lives. The findings may justify for clinical trials of the high-dose and new recombinant trivalent influenza vaccines in 50- to 64-year-old adults with chronic illnesses, such as heart or lung disease, diabetes, or cancer, to determine if they do provide considerably better protection than the currently recommended standard dose quadrivalent vaccine.
Tumor-destroying vaccines have emerged as a new weapon in the fight against cancer.
The Keck School of Medicine of USC launches a new study investigating a vaccine and oral medication to stop Alzheimer’s years before it begins
Karen Rasmussen knows the roadways and highways of Harris County too well. As driver for Harris Health System’s mobile immunization unit, she’s traveled nearly 30,000 miles in the last seven years crisscrossing the nation’s third largest county to vaccinate children.
Large boils, acid-like facial wounds, death by maiming of viscera. Leishmania parasites inflict suffering that is the stuff of parables. They're the second-deadliest parasites after malaria, and global warming is pushing them north. Can this new experimental vaccine someday stop them?
Scientists at The Scripps Research Institute (TSRI) have made a discovery that could speed efforts to develop a successful HIV vaccine.
In this month's release, find new embargoed research from a special AJPH supplement on public health emergency preparedness.
TAMPA, Fla. – Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus (HPV) vaccines has significantly reduced the number of those who develop and die from cervical cancer.
A vaccine that can literally eradicate the majority of cervical cancer cases shows long-term effectiveness in a study published today in The Lancet. This study in 18 countries extends the initial phase 3 efficacy and safety trial of the nine-valent human papilloma virus vaccine, Gardasil 9.
A toxin produced by a bacterium that causes urinary tract infections is related to, yet different in key ways from, the toxin that causes whooping cough, according to new research. The findings, which will be published in the Sept. 8 issue of The Journal of Biological Chemistry, could aid in the development of new vaccines.
In mouse experiments, researchers at University of California San Diego School of Medicine have discovered that drugs that activate the cells’ proteasome, or recycling center, tip the balance in favor of memory CD8+ T cells. This approach could be used to improve how well vaccines and immunotherapies work and how long they last.
Saint Louis University has received a $6.4 million task order from NIAID/NIH to study a treatment for MDR-TB, a worsening, deadly global health threat.
Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years. Researchers exploring combination therapies have recently discovered improved survival rates by up to one year when patients treated with a newly formulated chemotherapy regimen are also given radiation therapy.
Influenza vaccination rates in children may have decreased for the 2016-2017 influenza season because of a recommendation by the Centers for Disease Control and Prevention (CDC) that the nasal spray version of the vaccine not be used, according to Penn State College of Medicine researchers.
Health care provider recommendation of HPV vaccines could help decrease secondary cancers in childhood cancer survivors.
Research suggests health providers are key to boosting HPV vaccination rates of childhood cancer survivors, who, as a group, are at increased risk for second cancers associated with the human papillomavirus.
Texas Biomedical Research Institute UTHealth in Houston partner to test a modified TB vaccine that, if effective, could prove more powerful and provide longer lasting immunity.
Substance abuse is a continuing problem in the U.S., particularly with heroin and other opioids, to the point of being an epidemic. Treatments exist, but far too often patients relapse with devastating impacts on themselves and those around them. Now, scientists report that they have made progress toward a vaccine against the effects of fentanyl, a synthetic opioid, in combination with heroin.
Zachary Klase PhD summarizes the vaccine requirements for children heading to public schools and universities and explains why it is important and safe to be vaccinated.
The NIH has awarded Einstein researchers three grants totaling more than $12 million to protect against three deadly viruses—Ebola, Marburg and hantavirus. Research collaborations between Kartik Chandran, Ph.D., professor of microbiology & immunology and the Harold and Muriel Block Faculty Scholar in Virology, and Jonathan Lai, Ph.D., associate professor of biochemistry, have led to novel approaches for developing vaccines and treatments.
ASU Biodesign Institute scientist Qiang “Shawn” Chen has led his research team to develop the world’s first plant-based Zika vaccine that could be more potent, safer and cheaper to produce than any other efforts to date.
Group A Streptococcus bacteria — the cause of strep throat and flesh-eating infections — have been well studied for nearly a century. But researchers at University of California San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences recently made a surprising discovery: strep’s M protein alone wipes out macrophages, but not other types of immune cells. The macrophages’ self-sacrifice serves as an early warning of infection to the rest of the immune system.
Nadia Qureshi, MD, pediatric infectious disease physician at Loyola University Medical Center, and assistant professor of pediatrics at Loyola University Chicago Stritch School of Medicine, sheds light on some common myths about vaccines.
Southern Research scientist Dr. Raj Kalkeri says a new generation of antiviral therapies is urgently needed against hepatitis B, a chronic disease affecting 240 million people whose cure has proved elusive.
Pregnant women and young babies are among those most at risk for complications, hospitalization, and death from the flu. While doctors have long recommended flu shots for protection, experts weren’t exactly sure how the shots affect pregnancy.
SiO2 Medical Products, Inc. (“SMP”), a U.S.-based designer, developer, manufacturer, and supplier of pharmaceutical packaging, labware, and consumables products, and Sanaria Inc. (“Sanaria”), a U.S.-based developer, manufacturer, and supplier of vaccines, today announced the signing of an agreement for the development, manufacture, and supply of cryogenic vials for Sanaria’s malaria vaccine, Sanaria® PfSPZ Vaccine.
Dr. Sang-Moo Kang, professor in the Institute for Biomedical Sciences at Georgia State University, has renewed a four-year, $1.9 million federal grant to develop influenza vaccines that offer enhanced protection against a broad range of influenza virus strains.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right